Chesterford, U.K. 5 September, 2007 – Biotica Technology Ltd, a privately held biotechnology company, today announced the appointment of Dr Peter Ringrose as Non-Executive Director with imme diate effect. Dr. Ringrose, a highly regarded pharmaceutical industry veteran, will strengthen Biotica’s board as the company continues to exploit its polyketide drug discovery platform.

Dr Peter Ringrose most recently served as Chief Scientific Officer of Bristol-Myers Squibb Company and President of the Pharmaceutical Research Institute, where he was responsible for the discovery, preclinical and clinical development of pharmaceutical products worldwide. Previously, he was Senior Vice President and Head of Pfizer Central Research Europe. At Pfizer, Dr. Ringrose was responsible for teams involved in the discovery and development of many significant new medicines including Viagra. Prior to this he held senior positions at Sandoz Research Institute and Roche.

Dr. Ringrose currently serves as Chairman of the Biotechnology and Biological Sciences Research Council (BBSRC). He was a Non-Executive Director of Cambridge Antibody Technology and is currently a non-executive director of Astex Therapeutics Ltd and Rigel Pharmaceuticals Inc. He is a lifetime Honorary Pitt Fellow of Pembroke College Cambridge, a Council Member of the Foundation for Science and Technology UK and a Member of the New York Academy of Sciences President’s Council.

Mike Hayes, Chairman of Biotica, said, “I am delighted that Peter has agreed to join our Board. His exceptional pharmaceutical industry knowledge, together with a proven track record in overseeing the discovery and development of new medicines, will be of tremendous value to Biotica.”

Dr. Ringrose commented, “Biotica is at an exciting stage of its development with tremendous potential. The company’s productive relationship with Wyeth Pharmaceuticals to develop next-generation rapamycin-like drugs provides excellent validation of the value of Biotica’s polyketide engineering platform. I look forward to lending my experience to the company as it seeks to exploit other high value drug discovery opportunities.”

For further information, please contact:

Financial Dynamics

Ben Atwell
Tel. +44 207 831 3113
ben.atwell@fd.com